补肾健脾化瘀方对绝经后骨质疏松症妇女血清中PPARγ因子的影响

Effects of Bushen Jianpi Huayu prescription on PPARγ in serum of women with postmenopausal osteoporosis

目的:探讨补肾健脾化瘀方对绝经后骨质疏松症妇女血清中PPARγ因子的影响。方法:收集2013年9月-2014年9月期间就诊于广州军区广州总医院骨质疏松门诊的绝经后妇女患者23例,双能X线(DEXA)骨密度仪测量患者骨密度,根据WHO颁布的诊断标准,BMD T值评分大于-2.5为骨质疏松症,以此确定患者是否患有骨质疏松症。将收集的患者分为实验组(12例)和对照组(11例)。对照组只服用阿法骨化三醇+钙尔奇的基础治疗,实验组阿法骨化三醇+钙尔奇+补肾健脾化瘀方,治疗3个月后,门诊收集患者血液离心取血清。酶联免疫吸附法(ELISA)检测所收集的血清中PPARγ因子的表达浓度。结果:实验组绝经后骨质疏松症患者血清PPARγ因子的表达浓度低于于对照组(P<0.05)。结论:补肾健脾化瘀方能够降低绝经后骨质疏松症妇女血清中PPARγ因子的表达浓度,这说明补肾健脾化瘀方治疗绝经后妇女的骨质疏松症可能有一定的疗效。

Objective： To explore effects of Bushen Jianpi Huayu prescription on PPARγ in serum of women postmenopausal osteoporosis. Methods： 23 women with postmenopausal osteoporosis were divided into the experimental group （12 cases） and the control group （11 cases）. The contral group was given calcitriol soft capsules and caltrate, while the experimental group was given Bushen Jianpi Huayu prescription more. With 3 months of treatment, the level of PPARγ expressed in serum were detected by ELISA. Results： Compared with the control group, the level of PPARγ in serum ofpostmenopausal women were decreased （P〈0.05）. Conclusion： Bushen Jianpi Huayu prescription could reduce the level of PPARγ in serum of postmenopausal women, with some certain curative effect.